Hubei Biocause Pharmaceutical Co. Ltd. A | |
Stock Exchange | Shenzhen Stock Exchange |
EPS |
CNY0.26 |
Market Cap |
CNY31.52 B |
Shares Outstanding |
4.94 B |
Public Float |
1.54 B |
Address |
No. 132 Yangwan Road Jingmen Hubei 448000 China |
Employees | - |
Website | http://www.biocause.com |
Updated | 07/08/2019 |
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China. |